These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 3578323

  • 1. In vitro activity of ciprofloxacin against gram-positive cocci.
    Barry AL, Jones RN.
    Am J Med; 1987 Apr 27; 82(4A):27-32. PubMed ID: 3578323
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity of ciprofloxacin against gram-positive bacteria. An overview.
    Kayser FH, Novak J.
    Am J Med; 1987 Apr 27; 82(4A):33-9. PubMed ID: 3555058
    [Abstract] [Full Text] [Related]

  • 3. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC, Ribou G, Masquelier B.
    Pathol Biol (Paris); 1992 May 27; 40(5):461-5. PubMed ID: 1386667
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
    Cafiso V, Messina C, Santagati M, Campanile F, Bonfiglio G, Stefani S.
    Drugs Exp Clin Res; 2001 May 27; 27(3):107-11. PubMed ID: 11447768
    [Abstract] [Full Text] [Related]

  • 9. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS, Watters AA, Fritsche TR, Jones RN.
    BMC Infect Dis; 2007 Apr 18; 7():29. PubMed ID: 17442104
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
    Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.
    J Antimicrob Chemother; 2008 Jul 18; 62(1):116-21. PubMed ID: 18424792
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Sensitivity of methicillin resistant staphylococci to linezolid and some other antimicrobial agents].
    Ertek M, Yazgi H, Aktaş E, Ayyildiz A, Parlak M.
    Mikrobiyol Bul; 2003 Oct 18; 37(4):235-40. PubMed ID: 14748259
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.
    Fass RJ.
    Antimicrob Agents Chemother; 1991 Mar 18; 35(3):553-9. PubMed ID: 1903912
    [Abstract] [Full Text] [Related]

  • 17. Antibacterial activity of teicoplanin and vancomycin in combination with rifampicin, fusidic acid or fosfomycin against staphylococci on vein catheters.
    Simon VC, Simon M.
    Scand J Infect Dis Suppl; 1990 Mar 18; 72():14-9. PubMed ID: 2151061
    [Abstract] [Full Text] [Related]

  • 18. [Analysis on the susceptibility of fusidic acid for common gram positive bacteria].
    Liu C, Wang ZQ, Li R, Sun XG.
    Zhonghua Yan Ke Za Zhi; 2009 May 18; 45(5):452-5. PubMed ID: 19576070
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Overview of Scandinavian in vitro studies with ciprofloxacin.
    Forsgren A.
    Scand J Infect Dis Suppl; 1989 May 18; 60():16-22. PubMed ID: 2667106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.